Personal information

Chemokines, Melanoma, Breast Cancer, Drug resistance, Patient-derived models
United States

Biography

I am a cancer biologist with experience in basic and translational immunooncology. My research is focused on pre-clinical development of therapies that stimulate anti-tumor immunity by inducing “hot”, immune-cell enriched, tumor microenvironment. Currently, my group explores senescence-inducing therapies that activate pro-inflammatory pathways in tumor cells resulting in increased secretion of chemokines that promote immune cell homing into the tumor. We utilize mouse models of melanoma and mammary cancer, as well as patient-derived models, such as patient-derived organoids and patient-derived xenografts grown in humanized mice.

Activities

Employment (2)

Ohio State University: Columbus, OH, US

2019-08-17 to present | Assistant Professor (Pathology)
Employment
Source: Self-asserted source
Anna Vilgelm

Vanderbilt University School of Medicine: Nashville, TN, US

2011 to 2019 | Postdoc/Research Assistant Professor (Pharmacology)
Employment
Source: Self-asserted source
Anna Vilgelm

Education and qualifications (2)

Engelhardt Institute of Molecular Biology: Moscow, RU

2010 | PhD
Education
Source: Self-asserted source
Anna Vilgelm

Pirogov Russian National Research Medical University: Moscow, RU

2005 | MD
Education
Source: Self-asserted source
Anna Vilgelm

Professional activities (2)

American Association of Immunologists: Md., Md., US

2022 to present
Membership
Source: Self-asserted source
Anna Vilgelm

American Association for Cancer Research: PA, PA, US

2012 to present
Membership
Source: Self-asserted source
Anna Vilgelm

Funding (5)

A phase-1 trial of intraperitoneal 5-fluorouracil and oxaliplatin in patients with colorectal cancer and unresectable peritoneal metastasis.

2023-09-12 to 2025-08-31 | Grant
National Cancer Institute (Bethesda, US)
GRANT_NUMBER: R21CA282536
Source: Self-asserted source
Anna Vilgelm via DimensionsWizard

Harnessing Innate Immunity to Improve Metastatic Breast Cancer Therapy

2022-03-01 to 2025-02-28 | Grant
Congressionally Directed Medical Research Programs (Frederick, US)
GRANT_NUMBER:

W81XWH-22-1-0019

Source: Self-asserted source
Anna Vilgelm via DimensionsWizard

Harnessing Innate Immunity to Improve Metastatic Breast Cancer Therapy

2022 to 2025 | Grant
U.S. Department of Defense (DC, DC, US)
Source: Self-asserted source
Anna Vilgelm

Integrating biomimetic tissue engineering and multi-omics systems analysis to overcome CTCL drug resistance

2022 to 2024 | Grant
Pelotonia (OH, OH, US)
Source: Self-asserted source
Anna Vilgelm

Combining senescence-inducing and senolytic agents to improve melanoma therapy

2018-12-01 to 2023-11-30 | Grant
National Cancer Institute (Bethesda, US)
GRANT_NUMBER: R37CA233770
Source: Self-asserted source
Anna Vilgelm via DimensionsWizard

Works (49)

Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma

Cancers
2023-07 | Journal article | Author
Contributors: Chi Yan; Caroline A. Nebhan; Nabil Saleh; Rebecca Shattuck-Brandt; Sheau-Chiann Chen; Gregory D. Ayers; Vivian Weiss; ANN RICHMOND; Anna Vilgelm
Source: check_circle
Multidisciplinary Digital Publishing Institute

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.

Journal for immunotherapy of cancer
2023-05-01 | Journal article | Author
Contributors: Kumar A; Ramani V; Bharti V; Daniel de Lima Bellan; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM et al.
Source: Self-asserted source
Anna Vilgelm

Illuminating the mechanism of IL-6-mediated immunotherapy resistance.

Cell reports. Medicine
2023-01-01 | Journal article
Contributors: Vilgelm AE
Source: Self-asserted source
Anna Vilgelm

BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.

Cell reports
2022-12-01 | Journal article
Contributors: Bharti V; Watkins R; Kumar A; Shattuck-Brandt RL; Mossing A; Mittra A; Shen C; Tsung A; Alexander Davies; Hanel W et al.
Source: Self-asserted source
Anna Vilgelm

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology.

Journal of hematology & oncology
2022-01-10 | Journal article
Source: Self-asserted source
Anna Vilgelm

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.

Molecular cancer
2021-06-06 | Journal article
Source: Self-asserted source
Anna Vilgelm
grade
Preferred source (of 2)‎

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.

Frontiers in immunology
2021-06-01 | Journal article
Source: Self-asserted source
Anna Vilgelm

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.

Cell reports
2021-06-01 | Journal article
Source: Self-asserted source
Anna Vilgelm

Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.

Cell reports
2021-04-01 | Journal article
Source: Self-asserted source
Anna Vilgelm

Obtaining patient-derived cancer organoid cultures via fine-needle aspiration.

STAR protocols
2020-12-21 | Journal article
Source: Self-asserted source
Anna Vilgelm

High-throughput drug screening of fine-needle aspiration-derived cancer organoids.

STAR protocols
2020-12-16 | Journal article
Source: Self-asserted source
Anna Vilgelm

Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.

Cancer immunology research
2020-11-11 | Journal article
Source: Self-asserted source
Anna Vilgelm

Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine.

Tomography (Ann Arbor, Mich.)
2020-09-01 | Journal article
Source: Self-asserted source
Anna Vilgelm

Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.

Breast cancer research and treatment
2020-08-07 | Journal article
Source: Self-asserted source
Anna Vilgelm

Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids.

iScience
2020-07-24 | Journal article
Source: Self-asserted source
Anna Vilgelm

Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research
2020-03-31 | Journal article
Source: Self-asserted source
Anna Vilgelm

Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.

ACS nano
2020-01-02 | Journal article
Source: Self-asserted source
Anna Vilgelm

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

Science Translational Medicine
2019-08 | Journal article
Part of ISSN: 1946-6234
Contributors: Anna E. Vilgelm; Nabil Saleh; Rebecca Shattuck-Brandt; Kelsie Riemenschneider; Lauren Slesur; Sheau-Chiann Chen; C. Andrew Johnson; Jinming Yang; Ashlyn Blevins; Chi Yan et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy

Frontiers in Immunology
2019-02 | Journal article
Part of ISSN: 1664-3224
Contributors: Anna E. Vilgelm; Ann Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms

Cancer Immunology Research
2018-08 | Journal article
Part of ISSN: 2326-6066
Contributors: Jinming Yang; Amrendra Kumar; Anna E. Vilgelm; Sheau-Chiann Chen; Gregory D. Ayers; Sergey V. Novitskiy; Sebastian Joyce; Ann Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

MDM2 Antagonists Counteract Drug-Induced DNA Damage

EBioMedicine
2017-10 | Journal article
Part of ISSN: 2352-3964
Contributors: Anna E. Vilgelm; Priscilla Cobb; Kiran Malikayil; David Flaherty; C. Andrew Johnson; Dayanidhi Raman; Nabil Saleh; Brian Higgins; Brandon A. Vara; Jeffrey N. Johnston et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses

Clinical Cancer Research
2016 | Journal article
Part of ISSN: 1078-0432
Contributors: Jiqing Sai; Philip Owens; Sergey V. Novitskiy; Oriana E. Hawkins; Anna E. Vilgelm; Jinming Yang; Tammy Sobolik; Nicole Lavender; Andrew C. Johnson; Colt McClain et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Combinatorial approach to cancer immunotherapy: strength in numbers

Journal of Leukocyte Biology
2016-06-02 | Journal article
Part of ISSN: 0741-5400
Contributors: Anna E. Vilgelm; Douglas B. Johnson; Ann Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Using avatars to win the fight over BRAF inhibitor resistance

Pigment Cell & Melanoma Research
2016-05 | Journal article
Part of ISSN: 1755-1471
Contributors: Anna E. Vilgelm; Ann Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Nature Communications
2016-01 | Journal article
Part of ISSN: 2041-1723
Contributors: Douglas B. Johnson; Monica V. Estrada; Roberto Salgado; Violeta Sanchez; Deon B. Doxie; Susan R. Opalenik; Anna E. Vilgelm; Emily Feld; Adam S. Johnson; Allison R. Greenplate et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment

JNCI: Journal of the National Cancer Institute
2015 | Journal article
Part of ISSN: 1460-2105
Contributors: Anna E. Vilgelm; C. Andrew Johnson; Nripesh Prasad; Jinming Yang; Sheau-Chiann Chen; Gregory D. Ayers; Jeff S. Pawlikowski; Dayanidhi Raman; Jeffrey A. Sosman; Mark Kelley et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

Clinical Cancer Research
2015-07-07 | Journal article
Part of ISSN: 1078-0432
Contributors: Y. Liu; O. E. Hawkins; A. E. Vilgelm; J. S. Pawlikowski; J. A. Ecsedy; J. A. Sosman; M. C. Kelley; A. Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses

OncoImmunology
2015-03 | Journal article
Part of ISSN: 2162-402X
Contributors: Anna Vilgelm; Ann Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells

Cancer Research
2014-11 | Journal article
Part of ISSN: 0008-5472
Contributors: Anna E. Vilgelm; Jeff S. Pawlikowski; Yan Liu; Oriana E. Hawkins; Tyler A. Davis; Jessica Smith; Kevin P. Weller; Linda W. Horton; Colt M. McClain; Gregory D. Ayers et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment

Biomicrofluidics
2014-07 | Journal article
Part of ISSN: 1932-1058
Contributors: K. Hockemeyer; C. Janetopoulos; A. Terekhov; W. Hofmeister; A. Vilgelm; Lino Costa; J. P. Wikswo; A. Richmond
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

ChemInform Abstract: Preparation of (-)-Nutlin-3 Using Enantioselective Organocatalysis at Decagram Scale.

ChemInform
2014-03 | Journal article
Part of ISSN: 0931-7597
Contributors: Tyler A. Davis; Anna E. Vilgelm; Ann Richmond; Jeffrey N. Johnston
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Preparation of (−)-Nutlin-3 Using Enantioselective Organocatalysis at Decagram Scale

The Journal of Organic Chemistry
2013-10 | Journal article
Part of ISSN: 0022-3263
Contributors: Tyler A. Davis; Anna E. Vilgelm; Ann Richmond; Jeffrey N. Johnston
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescence

EMBO Molecular Medicine
2012-11 | Journal article
Part of ISSN: 1757-4676
Contributors: Yan Liu; Oriana E. Hawkins; Yingjun Su; Anna E. Vilgelm; Tammy Sobolik; Yee‐Mon Thu; Sara Kantrow; Ryan C. Splittgerber; Sarah Short; Katayoun I. Amiri et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

Clinical Cancer Research
2012-02 | Journal article
Part of ISSN: 1078-0432
Contributors: Y. Su; A. E. Vilgelm; M. C. Kelley; O. E. Hawkins; Y. Liu; K. L. Boyd; S. Kantrow; R. C. Splittgerber; S. P. Short; T. Sobolik et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Coordinated interaction of multifunctional members of the p53 family determines many key processes in multicellular organisms

Molecular Biology
2011-02 | Journal article
Part of ISSN: 0026-8933
Contributors: A. E. Vilgelm; A. I. Zaika; V. S. Prassolov
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells

Gastroenterology
2010-10 | Journal article
Part of ISSN: 0016-5085
Contributors: Jinxiong Wei; Toni A. Nagy; Anna Vilgelm; Elena Zaika; Seth R. Ogden; Judith Romero–Gallo; Maria B. Piazuelo; Pelayo Correa; Mary K. Washington; Wael El–Rifai et al.
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors

Oncogene
2010-08-02 | Journal article
Part of ISSN: 0950-9232
Contributors: A E Vilgelm; S-M Hong; M K Washington; J Wei; H Chen; W El-Rifai; A Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

683 Helicobacter pylori Actively Dysregulates p53 Tumor Suppressor

Gastroenterology
2010-05 | Journal article
Part of ISSN: 0016-5085
Contributors: Jinxiong Wei; Toni Nagy; Anna Vilgelm; Judith Romero-Gallo; Mary Kay Washington; Pelayo Correa; Wael M. El-Rifai; Richard M. Peek; Alexander Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

W1754 Role of p73 and Mechanisms of Its Regulation in Gastrointestinal Tumors

Gastroenterology
2010-05 | Journal article
Part of ISSN: 0016-5085
Contributors: Anna Vilgelm; Seung-Mo Hong; Jinxiong Wei; Wael M. El-Rifai; Alexander Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Interactions of the p53 Protein Family in Cellular Stress Response in Gastrointestinal Tumors

Molecular Cancer Therapeutics
2010-03-02 | Journal article
Part of ISSN: 1535-7163
Contributors: A. E. Vilgelm; M. K. Washington; J. Wei; H. Chen; V. S. Prassolov; A. I. Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

W1921 Interactions Within the p53 Protein Family Play Critical Role in Cancer Chemotherapeutic Treatment: New Insights Into Chemotherapeutic Drug Response in Gastrointestinal Tumors

Gastroenterology
2009-05 | Journal article
Part of ISSN: 0016-5085
Contributors: Anna Vilgelm; Jinxiong Wei; Kay Washington; Wael M. El-Rifai; Alexander Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Lentiviral vectors

Molecular Biology
2008-11 | Journal article
Part of ISSN: 0026-8933
Contributors: P. V. Spirin; A. E. Vilgelm; V. S. Prassolov
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Therapeutic prospects for p73 and p63: Rising from the shadow of p53

Drug Resistance Updates
2008-08 | Journal article
Part of ISSN: 1368-7646
Contributors: Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Interaction of Helicobacter pylori With Gastric Epithelial Cells Is Mediated by the p53 Protein Family

Gastroenterology
2008-05 | Journal article
Part of ISSN: 0016-5085
Contributors: Jinxiong Wei; Daniel O'Brien; Anna Vilgelm; Maria B. Piazuelo; Pelayo Correa; Mary K. Washington; Wael El-Rifai; Richard M. Peek; Alexander Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

ΔNp73α regulates MDR1 expression by inhibiting p53 function

Oncogene
2007-10 | Journal article
Part of ISSN: 0950-9232
Contributors: A Vilgelm; J X Wei; M B Piazuelo; M K Washington; V Prassolov; W El-Rifai; A Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

RNA interference: Biology and prospects of application in biomedicine and biotechnology

Molecular Biology
2006-05 | Journal article
Part of ISSN: 0026-8933
Contributors: A. E. Vilgelm; S. P. Chumakov; V. S. Prassolov
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

The gastrin gene promoter is regulated by p73 isoforms in tumor cells

Oncogene
2006-04 | Journal article
Part of ISSN: 0950-9232
Contributors: K Tomkova; W El-Rifai; A Vilgelm; M C Kelly; T C Wang; A I Zaika
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Akt-Mediated Phosphorylation and Activation of Estrogen Receptor α Is Required for Endometrial Neoplastic Transformation inPten+/−Mice

Cancer Research
2006-04-03 | Journal article
Part of ISSN: 0008-5472
Contributors: Anna Vilgelm; Zenglin Lian; Hong Wang; Stephen L. Beauparlant; Andres Klein-Szanto; Lora Hedrick Ellenson; Antonio Di Cristofano
Source: Self-asserted source
Anna Vilgelm via Crossref Metadata Search

Generation of Orthotopic Patient-Derived Xenograft in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma

Source: check_circle
Multidisciplinary Digital Publishing Institute

Peer review (8 reviews for 3 publications/grants)

Review activity for Cell reports. (2)
Review activity for Nature communications (5)
Review activity for npj precision oncology. (1)